Cost-effectiveness of Gemcitabine (Gemzar™) plus cisplatin versus etoposide plus cisplatin for advanced non small cell lung cancer (NSCLC) in Spain

被引：0

作者：

Rosell, R ^{[1
]}

Sacristan, JA ^{[1
]}

Duthie, T ^{[1
]}

Cardenal, F ^{[1
]}

Artal, A ^{[1
]}

Carrato, A ^{[1
]}

Lomas, M ^{[1
]}

Barneto, I ^{[1
]}

Bameto, I ^{[1
]}

Massuti, B ^{[1
]}

机构：

[1] Lilly Res Labs, Indianapolis, IN 46285 USA

来源：

ANNALS OF ONCOLOGY | 1998年 / 9卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

445P

引用

页码：92 / 93

页数：2

共 50 条

[1] Quality of life in non-small cell lung cancer patients receiving gemcitabine (Gemzar®) plus cisplatin or etoposide plus cisplatin
Rosell, R
Cardenal, F
Montes, A
Artal, A
Carrato, A
Lomas, M
Alberola, V
Barnetto, I
Massuti, B
Liepa, AM
[J]. ANNALS OF ONCOLOGY, 1998, 9 : 84 - 84
[2] Gemcitabine plus cisplatin in advanced non small cell lung cancer (NSCLC)
Casal, J
Huidobro, G
Grande, C
[J]. ANNALS OF ONCOLOGY, 1998, 9 : 103 - 103
[3] The effectiveness of vinorelbine plus cisplatin versus gemcitabine plus cisplatin in local advanced non-small cell lung cancer
Koemuercueoglu, B.
Aydogan, H.
Tekguel, S.
Cecen, E.
Yalniz, E.
Oezden, E. Pala
[J]. LUNG CANCER, 2006, 52 : S36 - S36
[4] Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).
Zhang, Y
Zhang, L
Li, N
Xu, F
Pan, ZK
Guang, ZZ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 702S - 702S
[5] A cost effectiveness analysis of bevacizumab plus cisplatin and gemcitabine (BCG) versus cetuximab plus vinorelbine and cisplatin (CVC) in patients with advanced or recurrent non-small cell cancer (NSCLC) in Spain
Castro Carpeno, Javier D.
Castro Gomez, Antonio J.
Walzer, Stefan
[J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S670 - S670
[6] Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
C C Earle
W K Evans
[J]. British Journal of Cancer, 1999, 80 : 815 - 820
[7] Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer
Earle, CC
Evans, WK
[J]. BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) : 815 - 820
[8] Analysis of cost-effectiveness of Bevacizumab plus cisplatin and gemcitabine (BCG) compared to an induction therapy with pemetrexed plus cisplatin (PC) in advanced or recurrent non-small cell lung cancer (NSCLC)
Bischoff, H.
Heigener, D.
Wiesner, C.
Walzer, S.
[J]. ONKOLOGIE, 2010, 33 : 131 - 132
[9] A COST-EFFECTIVENESS ANALYSIS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) COMPARED WITH PEMETREXED PLUS CISPLATIN (PC) FOR THE TREATMENT OF ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN GERMANY
Bischoff, H. G.
Heigener, D.
Wiesner, C.
Walzer, S.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A273 - A273
[10] Final results of randomized study of gemcitabine (G) plus cisplatin (P) versus etoposide (E) plus cisplatin in locally advanced or metastatic non small cell lung cancer (NSCLC)
Bousahba, A., Sr.
Bereksi-Reguig, F.
Seghier, F.
Boukerche, A.
Dali-Youcef, A.
Djellali, L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 4 5 →